Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 6
Submit an article Journal homepage
442
Views
17
CrossRef citations to date
0
Altmetric
Review

The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy

Mehrnaz Gharaee-Kermani University of Michigan Medical School, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, 2215 Fuller Road, 11R, Ann Arbor, MI 48105, USA +1 734 769 7100; +1 734 845 3128; [email protected]
, DVM MPH PhD,
Biao Hu University of Michigan Medical School, Department of Pathology, Ann Arbor, MI 48109, USA
, PhD,
Sem H Phan University of Michigan Medical School, Department of Pathology, Ann Arbor, MI 48109, USA
, MD PhD &
Margaret R Gyetko University of Michigan Medical School, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, 2215 Fuller Road, 11R, Ann Arbor, MI 48105, USA +1 734 769 7100; +1 734 845 3128; [email protected]
, MD
Pages 905-916 | Published online: 21 May 2008

Bibliography

  • Gharaee-Kermani M, Hu B, Thannickal VJ, et al. Current and emerging drugs for idiopathic pulmonary fibrosis. Exp Opin Emerging Drugs 2007;12:627-40
  • Thannickal VJ, Flaherty KR, Hyzyrcl RC, Lynch JP 3rd. Emerging drugs for idiopathic pulmonary fibrosis. Exp Opin Emerging Drugs 2005;10:707-27
  • American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the Society ATS, and ERS was adopted by the ATS board of directors, and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304
  • Raghu G, Weycker D, Edelsherg J, et al. Incidence and prevalence of pulmonary fibrosis deaths in the United States, 1979 – 1991; an analysis of multiple-cause mortality data. Am J Respir Crit Care Med 2006;174:810-6
  • Gharaee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Res 2005;11:3943-71
  • Strieter RM. Pathogenesis and natural history of usual interstitial pneumonia the whole story or the last chapter of a long novel. Chest 2005;128:526S-532S
  • Ask K, Gem M, Kolb M, Gauldie J. Targeting genes for treatment in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3:389-93
  • Gross TG, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-25
  • Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res 2007;24:819-41
  • Gharaee-Kermani M, Nozaki Y, Hatano K, Phan SH. Lung interlukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. Cytokine 2001;15:138-47
  • Gharaee-Kermani M, Phan SH. Lung interleukin-5 expression in murine bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 1997;16:438-47
  • Gharaee-Kermani M, Phan SH. Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr Pharm Res 2001;7:1083-103
  • Lama VN, Phan SH. The extrapulmonary origin of fibroblasts. Proc Am Thorac Soc 2006;3:373-76
  • Gharaee-Kermani M, Hatano K, Nozaki Y, Phan SH. Gender-based differences in bleomycin-induced pulmonary fibrosis. Am J Pathol 2005;166:1593-606
  • Swaisgood CM, French EL, Noga C, et al. The development of bleomycin induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 2000;157:177-87
  • Lazar MH, Chirstensen PJ, Du M, et al. Plasmiongen activator inhibitor-1 impairs alveolar epithelial repair by bindiny to vitronectin. Am J Respir Cell Mol Biol 2004;31:672-8
  • Sisson TH, Hanson KE, Subbotina N, et al. Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. Am J Lung Cell Mol Physiol 2002;283:L1023-32
  • Idell S. Coagulation, fibrinolysis, and fibrine déposition in acute lung injury. Crit Care Med 2003;31:S213-20
  • Hattori N, Mazuno S Yoshida Y, et al. The plasminogen activation system reduces fibrosis in the lung by hepatocyte growth factor-dependent mechanism. Am J Pathol 2004;164:1091-8
  • Olman MA, Mackman N, Gladson CL, et al. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995;96:1621-30
  • Bueno M, Salgado S, Beas-Zarate C, Borunda JA. Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF. J Gene Med 2006;8:1291-9
  • Matsuoka H, Sisson TH, Nashiuma T, Simon RH. Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix. Am J Respir Cell Mol Biol 2006;35:705-23
  • Gunther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000;83:853-60
  • Eltzman DT, MacCoy RO, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996;97:232-7
  • Hattori N, Degen GL, Sisson TH, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000;106:1341-50
  • Sisson TH, Hattori N, Xu Y, Simon RH. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther 1999;10:2315-23
  • Idell S. The matrix unloaded. Aerosolozed heparin or urokinase for pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:1268-9
  • Ploplis VA, Wiberding J, McLennan L, et al. A total fibrinogen deficiency is compatible with the development pulmonary fibrosis in mice. Am J Pathol 2000;157:703-8
  • Crippa MP. Urokinase-type plasminogen activator. Int J Biol Cell Biol 2007;39:690-4
  • Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004;25:450-5
  • Sheehan JJ, Tsirka SE. Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke. Glia 2005;50:340-50
  • Matsuo S, Lopez-Guisa JM, Cal X, et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 2005;67:2221-38
  • Carmeliet PL, Kieckens L, Schoonjans B, et al. Plasminogen activator inhibitor-1 gene-deficient mice. 1. generation by homologous recombination and characterization. J Clin Invest 1993;92:2746-55
  • Cale JM, Lawrence DA. Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets 2007;8:971-81
  • Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007;97:336-42
  • Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997;9:714-24
  • Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 1998;91:255-85
  • Rifkin DB, Mazzieri R, Munger JS, et al. Proteolytic control of growth factor availability. APMIS 1999;107:80-5
  • Salgado S, García J, Vera J, et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000;2:545-55
  • Steler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996;148:1345-50
  • Alfano D, Franco P, Voccal I, et al. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005;93:205-11
  • Sidernius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22
  • Hildenbrand R, Gandhari M, Stoebel P. The urokinase system-role of cell proliferation and apoptosis. Histol Histopathol 2008;23:227-36
  • Carmeliet L, Schoonjans L, Kieckens B, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419-24
  • Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5
  • Wei Y, Eble JA, Wang Z, et al. Urokinase receptor promotes β1 integrin function through interactions with integrin α5β1. Mol Biol Cell 2001;12:2975-86
  • Resnati M, Pallavicini I, Wang JM, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002;99:1359-64
  • Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002;283:F209-20
  • Howell DC, Laurent GJ, Chambers RC. Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis. Biochem Soc Trans 2002;30:211-6
  • Kotani I, Sato A, Hayakawa H, et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995;77:493-504
  • Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982;3:35-56
  • Idell S, Gonzalez K, Bradford H, et al. Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII. Am Rev Respir Dis 1987;136:1466-74
  • Bertozzi P, Astedt B, Zenzius L, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990;322:890-7
  • Gunther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;161:454-62
  • Sisson TH, Simon RH. Cell specific control of coagulation and fibrinolysis within the lung. Thromb Haemost 2004;92:435-7
  • Hart DA, Whidden P, Green F, et al. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med 1994;17:69-76
  • Ikeda T, Hirose N, Koto H, et al. Fibrin deposition and fibrinolysis in the pathogenesis of pulmonary fibrosis. Nihon Kyobu Shikkan Gakkai Zasshi 1989;27:448-51
  • Gunther A, Lubke N, Ermert M, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003;168:1358-65
  • Wang H, Zhang Y, Heuckeroth RO. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett 2007;581:3098-104
  • Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993;143:949-58
  • Naldini L, Tamagnone K, Vigna E, et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992;11:4825-33
  • Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60-6
  • Dohi M, Hasegawa T, Yamamoto K, Marshall BC. Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000;162:2302-7
  • Watanabe M, Ebina M, Orson FM, et al. Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Mol Ther 2005;12:58-67
  • Selman M. From anti-inflammatory drugs through antifibrotic agents to lung transportation. A long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis. Chest 2002;123:759-61
  • Lynch JP 3rd, White E, Flaherty K. Corticosteroids in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2001;7:298-308
  • Intermune, Inc. Intermune Capacity Trials - Pirfenidone trial in patients with IPF (idiopathic pulmonary fibrosis). A detail of trials involving the use of pirfenidone for IPF patients. Available from: http://www.capacitytrials.com/wt/page/index [Last accessed 12 March 2008]
  • A phase II/III double-blind, randomized, placebo-controlled multi-centre study to assess the efficacy, safety, and tolerability of bosentan in patients with IPF (‘BUILD-1’: Bosentan Use in Interstitial Lung Disease) has been completed, and a detail of these trails is available from: www.actelion.com [Last accessed 12 March 2008]
  • A detail of trails IFIGENIA (Idiopathic pulmonary Fibrosis International Group Exploring NAC 1 Annual) study. Available from: http://www.zambongroup.com [Last accessed 3 January 2008]
  • Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. Pharmacological therapy for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999;160:1771-7
  • Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9
  • Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33
  • Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005;26:693-702
  • Idell S, Gonzalez KK, MacArthur CK, et al. Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets: characterization and relationship to fibrin deposition and fibrosis. Am Rev Respir Dis 1987;136:124-33
  • Barazzone C, Belin D, Piguet P-F, et al. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest 1996;98:2666-73
  • Idell S. Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. Crit Care Med 2002;30:S274-80
  • Stempien-Otero A, Plawman A, Maznarich J, et al. Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J Biol Chem 2006;281:15345-51
  • Yasui H, Gabazza EC, Tamaki S, et al. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 2001;163:1660-8
  • Naldini L, Vigna E, Bardelli A, et al. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 1995;270:603-11
  • Van leer C, Stutz M, Haeberli A, Geiser T. Urokinase plasminogen activator released by alveolar epithelial cells modulates alveolar epithelial repair in viro. Thromb Haemost 2005;94:1257-64
  • Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-82
  • Chapman HA, Allen CL, Stone OL. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 1986;133:437-43
  • Howell DC, Goldsack NR, Marshall RP, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001;159:1383-95
  • Trejo J, Connolly AJ, Coughlin SR. The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. J Biol Chem 1996;271:21536-41
  • Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 1998;274:C1429-52
  • Grotendorst GR. Identification and development of novel antifibrotic agents. Expert Opin Investig Drugs 1997;6:777-81
  • Chambers RC, Laurent GJ. Coagulation cascade proteases and tissue fibrosis. Biochem Soc Trans 2002;30:194-200
  • Basset F, Ferrans VJ, Soler P, et al. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol 1986;122:443-61
  • Bezerra JA, Currier AR, Melin-Aldana H, et al. Plasminogen activators direct reorganization of the liver lobule after acute injury. Am J Pathol 2001;158:921-9
  • Bezzerra JA, Bugge TH, Melin-Aldana H, et al. Plasminogen deficiency leads to impaired remodelling after a toxic injury to the liver. Proc Natl Acad Sci USA 1999;96:15143-8
  • Yaekashiwa M, Nakayama S, Ohnuma K, et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycina morphologic study. Am J Respir Crit Care Med 1997;156:1937-44
  • Pepper MS, Matsumoto K, Nakamura T, et al. Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 1992;267:20493-6
  • Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 1996;16:1115-25
  • Münster AMB, Rasmussen L, Sidelmann J, et al. Effects of inhaled plasminogen activator on the haemostatic balance in traumatised pigs. Blood Coagul Fibrinolysis 2002;13:591-601
  • Münster AMB, Bendstrup KE, Ingemann Jensen J, Gram J. Jet and ultrasonic nebulization of single chain urokinase plasminogen activator (scu-PA). J Aerosol Med 2000;13:325-33
  • Gram J, Münster AM, Dilling-Hansen B, et al. Inhalation/intravenous recombinant tissue plasminogen activator and inhaled heparin in patients with acute respiratory distress syndrome. Fibrinolysis Proteolysis 1999;13:209-12
  • Mizuno S, Matsumoto K, Li MY, Nakamura T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 2005;19:580-2
  • Horowitz JC, Roger DS, Simon RH, et al. Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am J Respir Cell Mol Biol 2007;38:78-87

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.